KATY REZVANI

TitleProfessor
InstitutionMD Anderson
DepartmentStem Cell Transplantation
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Rezvani K. Chimeric antigen receptor natural killer cells for the treatment of patients with B-cell malignancies. Clin Adv Hematol Oncol. 2020 09; 18(9):543-545. PMID: 33006583.
      Citations:    Fields:    
    2. Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 08 17; 22(8):1214-1225. PMID: 32152626.
      Citations: 2     Fields:    
    3. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2020 Jun 30; 1-8. PMID: 32604096.
      Citations:    Fields:    
    4. Rezvani K, Shpall EJ, Marin D. CAR-Transduced Natural Killer Cells. Reply. N Engl J Med. 2020 05 07; 382(19):1866-1867. PMID: 32374976.
      Citations:    Fields:    Translation:Cells
    5. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306. PMID: 32236526.
      Citations:    Fields:    
    6. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865. PMID: 31961918.
      Citations: 1     Fields:    Translation:HumansCells
    7. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 May 15; 126(10):2193-2205. PMID: 32125707.
      Citations: 1     Fields:    
    8. Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020 May 15; 126(10):2183-2192. PMID: 32101640.
      Citations:    Fields:    
    9. Rezvani K. Adoptive cell therapy using engineered natural killer cells. Bone Marrow Transplant. 2019 08; 54(Suppl 2):785-788. PMID: 31431708.
      Citations: 8     Fields:    Translation:HumansCells
    10. El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, El Chaer F, El-Haddad D, Prayag A, Nesher L, Rezvani K, Shpall E, Chemaly RF. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2019 02 23; 219(6):898-907. PMID: 30295846.
      Citations: 7     Fields:    Translation:HumansCells
    11. Rezvani K, Marin D. Allogeneic BK Virus-Specific T Cells for PML. N Engl J Med. 2019 01 03; 380(1):106. PMID: 30601739.
      Citations: 2     Fields:    Translation:HumansCells
    12. Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, Mohd Mustapa MF, Exton LS, Kanfer E, Rezvani K, Dearden CE, Morris SL. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019 03; 180(3):496-526. PMID: 30561020.
      Citations: 5     Fields:    Translation:Humans
    13. Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447. PMID: 29567676.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    14. Lee J, Thall PF, Rezvani K. Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times. J R Stat Soc Ser C Appl Stat. 2019 Feb; 68(2):461-474. PMID: 31105345.
      Citations:    
    15. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281. PMID: 29479067.
      Citations:    Fields:    Translation:Humans
    16. Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant. 2018 07; 24(7):1322-1340. PMID: 29471034.
      Citations: 12     Fields:    Translation:Humans
    17. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520. PMID: 29448058.
      Citations: 6     Fields:    Translation:Humans
    18. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257. PMID: 29386198.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    19. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103. PMID: 29097493.
      Citations: 449     Fields:    Translation:HumansAnimals
    20. Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2018 04; 32(4):960-970. PMID: 28972595.
      Citations: 17     Fields:    Translation:HumansCells
    21. Cossarizza A, Chang HD, Radbruch A, Akdis M, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavani A, Chattopadhyay PK, Cheng Q, Chow S, Clerici M, Cooke A, Cosma A, Cosmi L, Cumano A, Dang VD, Davies D, De Biasi S, Del Zotto G, Della Bella S, Dellabona P, Deniz G, Dessing M, Diefenbach A, Di Santo J, Dieli F, Dolf A, Donnenberg VS, Dörner T, Ehrhardt GRA, Endl E, Engel P, Engelhardt B, Esser C, Everts B, Dreher A, Falk CS, Fehniger TA, Filby A, Fillatreau S, Follo M, Förster I, Foster J, Foulds GA, Frenette PS, Galbraith D, Garbi N, García-Godoy MD, Geginat J, Ghoreschi K, Gibellini L, Goettlinger C, Goodyear CS, Gori A, Grogan J, Gross M, Grützkau A, Grummitt D, Hahn J, Hammer Q, Hauser AE, Haviland DL, Hedley D, Herrera G, Herrmann M, Hiepe F, Holland T, Hombrink P, Houston JP, Hoyer BF, Huang B, Hunter CA, Iannone A, Jäck HM, Jávega B, Jonjic S, Juelke K, Jung S, Kaiser T, Kalina T, Keller B, Khan S, Kienhöfer D, Kroneis T, Kunkel D, Kurts C, Kvistborg P, Lannigan J, Lantz O, Larbi A, LeibundGut-Landmann S, Leipold MD, Levings MK, Litwin V, Liu Y, Lohoff M, Lombardi G, Lopez L, Lovett-Racke A, Lubberts E, Ludewig B, Lugli E, Maecker HT, Martrus G, Matarese G, Maueröder C, McGrath M, McInnes I, Mei HE, Melchers F, Melzer S, Mielenz D, Mills K, Mirrer D, Mjösberg J, Moore J, Moran B, Moretta A, Moretta L, Mosmann TR, Müller S, Müller W, Münz C, Multhoff G, Munoz LE, Murphy KM, Nakayama T, Nasi M, Neudörfl C, Nolan J, Nourshargh S, O'Connor JE, Ouyang W, Oxenius A, Palankar R, Panse I, Peterson P, Peth C, Petriz J, Philips D, Pickl W, Piconese S, Pinti M, Pockley AG, Podolska MJ, Pucillo C, Quataert SA, Radstake TRDJ, Rajwa B, Rebhahn JA, Recktenwald D, Remmerswaal EBM, Rezvani K, Rico LG, Robinson JP, Romagnani C, Rubartelli A, Ruckert B, Ruland J, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Sawitzki B, Scheffold A, Schiemann M, Schildberg F, Schimisky E, Schmid SA, Schmitt S, Schober K, Schüler T, Schulz AR, Schumacher T, Scotta C, Shankey TV, Shemer A, Simon AK, Spidlen J, Stall AM, Stark R, Stehle C, Stein M, Steinmetz T, Stockinger H, Takahama Y, Tarnok A, Tian Z, Toldi G, Tornack J, Traggiai E, Trotter J, Ulrich H, van der Braber M, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Volk HD, von Volkmann K, Waisman A, Walker R, Ward MD, Warnatz K, Warth S, Watson JV, Watzl C, Wegener L, Wiedemann A, Wienands J, Willimsky G, Wing J, Wurst P, Yu L, Yue A, Zhang Q, Zhao Y, Ziegler S, Zimmermann J. Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol. 2017 10; 47(10):1584-1797. PMID: 29023707.
      Citations: 76     Fields:    Translation:HumansAnimalsCells
    22. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018 02; 32(2):520-531. PMID: 28725044.
      Citations: 78     Fields:    Translation:HumansCells
    23. Rezvani K, Rouce R, Liu E, Shpall E. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 08 02; 25(8):1769-1781. PMID: 28668320.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    24. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1359-1366. PMID: 28506845.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    25. Forte M, Lowdell M, Rezvani K. Welcome to ISCT 2017 London. Cytotherapy. 2017 05; 19(5S):S1-S2. PMID: 28473050.
      Citations:    Fields:    
    26. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer. 2017 Jul 15; 123(14):2661-2670. PMID: 28324640.
      Citations: 4     Fields:    Translation:Humans
    27. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466. PMID: 28295190.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    28. Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, Thonhoff JR, Alsuliman AS, Shpall EJ, Rezvani K, Appel SH. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017 03 09; 2(5):e89530. PMID: 28289705.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    29. Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017 01; 102(1):110-117. PMID: 27540139.
      Citations: 5     Fields:    Translation:Humans
    30. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76. PMID: 27482888.
      Citations: 95     Fields:    Translation:HumansCellsCTClinical Trials
    31. Bigley AB, Rezvani K, Shah N, Sekine T, Balneger N, Pistillo M, Agha N, Kunz H, O'Connor DP, Bollard CM, Simpson RJ. Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans. Clin Exp Immunol. 2016 08; 185(2):239-51. PMID: 26940026.
      Citations: 16     Fields:    Translation:HumansCells
    32. Langman LJ, Nesher L, Shah DP, Azzi JM, Shpall EJ, Rezvani K, Black JL, Chemaly RF. Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. J Mol Diagn. 2016 09; 18(5):638-642. PMID: 27371869.
      Citations: 1     Fields:    Translation:Humans
    33. Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016 07 15; 122(14):2186-96. PMID: 27142181.
      Citations: 20     Fields:    Translation:Humans
    34. Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant. 2016 05; 16(5):1492-502. PMID: 26608093.
      Citations: 5     Fields:    Translation:HumansCells
    35. Nesher L, Shah DP, Ariza-Heredia EJ, Azzi JM, Siddiqui HK, Ghantoji SS, Marsh LY, Michailidis L, Makedonas G, Rezvani K, Shpall EJ, Chemaly RF. Utility of the Enzyme-Linked Immunospot Interferon-?-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2016 Jun 01; 213(11):1701-7. PMID: 26908740.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    36. Rouce RH, Shaim H, Sekine T, Weber G, Ballard B, Ku S, Barese C, Murali V, Wu MF, Liu H, Shpall EJ, Bollard CM, Rabin KR, Rezvani K. The TGF-ß/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11. PMID: 26621337.
      Citations: 30     Fields:    Translation:HumansCells
    37. Cata JP, Conrad C, Rezvani K. Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes. Scientifica (Cairo). 2015; 2015:732438. PMID: 26576322.
      Citations:    
    38. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant. 2015 Jun; 50 Suppl 2:S55-62. PMID: 26039209.
      Citations: 8     Fields:    Translation:Humans
    39. Abudayyeh A, Truong LD, Beck LH, Weber DM, Rezvani K, Abdelrahim M. Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction? Clin Kidney J. 2015 Aug; 8(4):440-4. PMID: 26251713.
      Citations:    
    40. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92. PMID: 25778529.
      Citations: 37     Fields:    Translation:HumansCells
    41. Bigley AB, Rezvani K, Pistillo M, Reed J, Agha N, Kunz H, O'Connor DP, Sekine T, Bollard CM, Simpson RJ. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: impact of latent cytomegalovirus infection and catecholamine sensitivity. Brain Behav Immun. 2015 Oct; 49:59-65. PMID: 25578514.
      Citations: 8     Fields:    Translation:HumansCells
    42. Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Shpall EJ. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood. 2015 Feb 26; 125(9):1502-6. PMID: 25428215.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    43. Jain NA, Ito S, Tian X, Kurlander R, Battiwalla M, Lu K, Savani BN, Malkovska V, Rezvani K, Le RQ, Shenoy A, Hourigan CS, Keyvanfar K, Koklanaris E, Superata J, Muranski P, Barrett AJ, Yong ASM. Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplant. 2015 Feb; 50(2):189-196. PMID: 25387087.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    44. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014 Dec; 3(12):1435-43. PMID: 25378655.
      Citations: 21     Fields:    Translation:Humans
    45. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1975-81. PMID: 25263628.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    46. Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S18-22. PMID: 25486950.
      Citations: 2     Fields:    Translation:HumansCells
    47. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45. PMID: 25051962.
      Citations: 64     Fields:    Translation:HumansCells
    48. Liu X, Robinson SN, Setoyama T, Tung SS, D'Abundo L, Shah MY, Yang H, Yvon E, Shah N, Yang H, Konopleva M, Garcia-Manero G, McNiece I, Rezvani K, Calin GA, Shpall EJ, Parmar S. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant. 2014 Jun; 49(6):793-9. PMID: 24710569.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    49. Sane S, Abdullah A, Boudreau DA, Autenried RK, Gupta BK, Wang X, Wang H, Schlenker EH, Zhang D, Telleria C, Huang L, Chauhan SC, Rezvani K. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. Cell Death Dis. 2014 Mar 13; 5:e1118. PMID: 24625977.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    50. Bear AS, Hanley PJ, Bosque DM, Cruz CR, Kaur I, Liu H, Kebriaei P, Hosing C, Rezvani K, Oran B, De Lima MJ, Bollard CM, Shpall EJ. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy. 2014 Aug; 16(8):1153-7. PMID: 24582458.
      Citations: 2     Fields:    Translation:HumansCells
    51. Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014 May; 99(5):836-47. PMID: 24488563.
      Citations: 46     Fields:    Translation:HumansCells
    52. Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):e105-9. PMID: 24502832.
      Citations: 3     Fields:    Translation:Humans
    53. Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic D. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. Br J Haematol. 2014 Feb; 164(4):608-10. PMID: 24219400.
      Citations:    Fields:    Translation:Humans
    54. Bigley AB, Rezvani K, Chew C, Sekine T, Pistillo M, Crucian B, Bollard CM, Simpson RJ. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain Behav Immun. 2014 Jul; 39:160-71. PMID: 24200514.
      Citations: 20     Fields:    Translation:HumansCells
    55. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5. PMID: 24169268.
      Citations: 6     Fields:    Translation:HumansCells
    56. Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100. PMID: 24480547.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    57. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781. PMID: 24204673.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    58. Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy. 2014 Jan; 16(1):84-9. PMID: 24094497.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    59. de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013 Jul 11; 122(2):227-38. PMID: 23719297.
      Citations: 26     Fields:    Translation:HumansCells
    60. Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, MacDonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant. 2013 Oct; 48(10):1324-8. PMID: 23686098.
      Citations: 2     Fields:    Translation:HumansCells
    61. Loaiza S, Haynes R, Bray E, Finn SA, Rezvani K, Apperley J, Davis J. Donor lymphocyte collections using the spectra Optia MNC version 5. Transfus Apher Sci. 2013 Apr; 48(2):171. PMID: 23809820.
      Citations: 2     Fields:    Translation:HumansCells
    62. Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013 Apr 04; 121(14):2739-42. PMID: 23380743.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    63. Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J. Cancer vaccines and T cell therapy. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S97-S101. PMID: 23041602.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    64. Ali S, Sergeant R, O'Brien SG, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood. 2012 Jul 19; 120(3):697-8. PMID: 22822001.
      Citations: 3     Fields:    Translation:Humans
    65. Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood. 2012 May 24; 119(21):5030-6. PMID: 22371885.
      Citations: 39     Fields:    Translation:HumansCells
    66. Rezvani K. Aurora: a new direction for a new dawn. Blood. 2012 Jan 12; 119(2):322-3. PMID: 22247517.
      Citations:    Fields:    Translation:HumansAnimalsCells
    67. Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L. BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol. 2012 Mar; 87(3):298-304. PMID: 22231203.
      Citations: 14     Fields:    Translation:HumansCells
    68. Rezvani K, Yong AS, Mielke S, Savani BN, Jafarpour B, Eniafe R, Le RQ, Musse L, Boss C, Childs R, John Barrett A. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother. 2012 Jul; 61(7):1125-36. PMID: 22198310.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    69. Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, Reid A, Rezvani K, Foroni L, Goldman J, Marin D. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood. 2012 Feb 23; 119(8):1838-43. PMID: 22174159.
      Citations: 18     Fields:    Translation:HumansCells
    70. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012 Jan 20; 30(3):232-8. PMID: 22067393.
      Citations: 136     Fields:    Translation:HumansCells
    71. Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla A. Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol. 2012 Apr; 157(1):125-7. PMID: 22050411.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    72. Rezvani K. CD40-ligand/interleukin-2 vaccines in chronic lymphocytic leukemia: the impact of vaccine design. Cytotherapy. 2011 Oct; 13(9):1029-30. PMID: 21916777.
      Citations:    Fields:    Translation:HumansCells
    73. Rezvani K, de Lavallade H. Vaccination strategies in lymphomas and leukaemias: recent progress. Drugs. 2011 Sep 10; 71(13):1659-74. PMID: 21902290.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    74. Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 2012 Feb; 26(2):296-302. PMID: 21844874.
      Citations: 13     Fields:    Translation:Humans
    75. Rezvani K, de Lavallade H. Improving outcomes in myeloid leukemia patients: does a new DNA vaccine hold the answer? Expert Rev Vaccines. 2011 Jul; 10(7):933-5. PMID: 21806391.
      Citations:    Fields:    Translation:Humans
    76. Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, Macdonald D, Dazzi F, Milojkovic D, Foroni L, Pavlu J, Sargent J, Le Dieu R, Goldman JM, Apperley J, Szydlo R. EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant. 2012 Feb; 18(2):235-40. PMID: 21723225.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    77. Mielke S, McIver ZA, Shenoy A, Fellowes V, Khuu H, Stroncek DF, Leitman SF, Childs R, Battiwalla M, Koklanaris E, Haggerty J, Savani BN, Rezvani K, Barrett AJ. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1855-61. PMID: 21684344.
      Citations: 20     Fields:    Translation:HumansCells
    78. Dong G, Ferguson JM, Duling AJ, Nicholas RG, Zhang D, Rezvani K, Fang S, Monteiro MJ, Li S, Li XJ, Wang H. Modeling pathogenesis of Huntington's disease with inducible neuroprogenitor cells. Cell Mol Neurobiol. 2011 Jul; 31(5):737-47. PMID: 21452052.
      Citations: 7     Fields:    Translation:AnimalsCells
    79. Rezvani K. Peptide vaccine therapy for leukemia. Int J Hematol. 2011 Mar; 93(3):274-280. PMID: 21380929.
      Citations: 4     Fields:    Translation:HumansAnimalsPHPublic Health
    80. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011 Apr 07; 117(14):3733-6. PMID: 21346253.
      Citations: 79     Fields:    Translation:Humans
    81. Gerrard G, Mudge K, Stewart R, Foskett P, Stevens D, Khorashad JS, Szydlo R, Rezvani K, Marin D, Reid A, Apperley J, Goldman J, Foroni L. Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies. Am J Hematol. 2011 Mar; 86(3):313-5. PMID: 21328433.
      Citations:    Fields:    Translation:Humans
    82. Yong AS, Stephens N, Weber G, Li Y, Savani BN, Eniafe R, Keyvanfar K, Kurlander R, Rezvani K, Barrett AJ. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia. 2011 Apr; 25(4):629-37. PMID: 21252986.
      Citations: 10     Fields:    Translation:HumansCells
    83. Rezvani K. Posttransplantation vaccination: concepts today and on the horizon. Hematology Am Soc Hematol Educ Program. 2011; 2011:299-304. PMID: 22160049.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    84. Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R, Barrett AJ. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica. 2011 Mar; 96(3):432-40. PMID: 21134985.
      Citations: 44     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    85. de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani K. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011 Feb; 96(2):307-14. PMID: 20971824.
      Citations: 22     Fields:    Translation:HumansCellsPHPublic Health
    86. Ibrahim AR, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad JS, Foroni L, Reid A, de Lavallade H, Rezvani K, Dazzi F, Apperley JF, Goldman JM, Marin D. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010 Dec 16; 116(25):5497-500. PMID: 20833982.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    87. Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant. 2011 May; 17(5):591-7. PMID: 20732435.
      Citations: 20     Fields:    Translation:HumansCells
    88. Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood. 2010 Aug 12; 116(6):1014-6. PMID: 20705771.
      Citations: 5     Fields:    Translation:Humans
    89. Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K. Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transplant. 2011 May; 17(5):632-9. PMID: 20708085.
      Citations: 6     Fields:    Translation:HumansCells
    90. Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K. Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood. 2010 Sep 23; 116(12):2033-9. PMID: 20562327.
      Citations: 13     Fields:    Translation:HumansCells
    91. Venepalli N, Rezvani K, Mielke S, Savani BN. Role of allo-SCT for CML in 2010. Bone Marrow Transplant. 2010 Nov; 45(11):1579-86. PMID: 20531284.
      Citations: 4     Fields:    Translation:Humans
    92. Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia. 2010 Jun; 24(6):1243-5. PMID: 20445576.
      Citations: 18     Fields:    Translation:Humans
    93. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010 May 10; 28(14):2381-8. PMID: 20385986.
      Citations: 219     Fields:    Translation:Humans
    94. Pavlu J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010 May 20; 115(20):4018-20. PMID: 20304808.
      Citations: 23     Fields:    Translation:Humans
    95. Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant. 2009 Dec; 44(12):769-77. PMID: 19855439.
      Citations: 20     Fields:    Translation:Humans
    96. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM, Marin D. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2010 Feb; 95(2):224-31. PMID: 19833633.
      Citations: 35     Fields:    Translation:Humans
    97. Barrett J, Rezvani K. Immunotherapy: Can we include vaccines with stem-cell transplantation? Nat Rev Clin Oncol. 2009 Sep; 6(9):503-5. PMID: 19707241.
      Citations: 6     Fields:    Translation:Humans
    98. Khorashad JS, Wagner S, Greener L, Marin D, Reid A, Milojkovic D, Patel H, Willimott S, Rezvani K, Gerrard G, Loaiza S, Davis J, Goldman J, Melo J, Apperley J, Foroni L. The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. Haematologica. 2009 Jun; 94(6):861-4. PMID: 19377081.
      Citations: 3     Fields:    Translation:HumansCells
    99. Marin D, Khorashad JS, Foroni L, Milojkovic D, Szydlo R, Reid AG, Rezvani K, Bua M, Goldman JM, Apperley JF. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol. 2009 May; 145(3):373-5. PMID: 19344397.
      Citations: 5     Fields:    Translation:HumansCells
    100. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood. 2009 Mar 05; 113(10):2245-55. PMID: 18988867.
      Citations: 41     Fields:    Translation:HumansCells
    101. Rezvani K. PR1 vaccination in myeloid malignancies. Expert Rev Vaccines. 2008 Sep; 7(7):867-75. PMID: 18767937.
      Citations: 7     Fields:    Translation:HumansCells
    102. Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2008 Sep; 21(3):437-53. PMID: 18790448.
      Citations: 21     Fields:    Translation:HumansCells
    103. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JF. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008 Dec 01; 112(12):4437-44. PMID: 18716134.
      Citations: 103     Fields:    Translation:Humans
    104. Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia. 2008 Sep; 22(9):1721-7. PMID: 18548092.
      Citations: 23     Fields:    Translation:HumansCells
    105. Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol. 2008 Jan; 45(1):39-48. PMID: 18179968.
      Citations: 17     Fields:    Translation:HumansCells
    106. Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR, Fan Y, Gostick E, Price DA, Scotto C, Read EJ, Barrett AJ. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood. 2008 Apr 15; 111(8):4392-402. PMID: 17878399.
      Citations: 37     Fields:    Translation:HumansCells
    107. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 01; 111(1):236-42. PMID: 17875804.
      Citations: 111     Fields:    Translation:HumansCellsCTClinical Trials
    108. Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L, Superata J, Kurlander R, Singh A, Childs R, Barrett AJ. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Oct; 13(10):1216-23. PMID: 17889359.
      Citations: 40     Fields:    Translation:Humans
    109. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS, Zeilah J, Kurlander R, Srinivasan R, Childs R, Hensel N, Barrett AJ. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007 Oct; 21(10):2145-52. PMID: 17673900.
      Citations: 61     Fields:    Translation:HumansCells
    110. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price DA, Douek DC, Barrett AJ. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007 Sep 15; 110(6):1924-32. PMID: 17505014.
      Citations: 59     Fields:    Translation:HumansCells
    111. Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J, Kurlander R, Ghetie V, Read EJ, Solomon SR, Vitetta ES, Barrett AJ. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood. 2007 Sep 01; 110(5):1689-97. PMID: 17478639.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    112. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol. 2007 May; 148(2):189-98. PMID: 17437417.
      Citations: 12     Fields:    Translation:Humans
    113. Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ, Young NS. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007 Sep 01; 110(5):1603-6. PMID: 17463169.
      Citations: 56     Fields:    Translation:HumansCellsCTClinical Trials
    114. Yong AS, Rezvani K, Savani BN, Eniafe R, Mielke S, Goldman JM, Barrett AJ. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood. 2007 Jul 15; 110(2):770-5. PMID: 17412886.
      Citations: 15     Fields:    Translation:Humans
    115. Grube M, Moritz S, Obermann EC, Rezvani K, Mackensen A, Andreesen R, Holler E. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res. 2007 Feb 01; 13(3):1053-60. PMID: 17289902.
      Citations: 13     Fields:    Translation:HumansCells
    116. Rezvani K, Price DA, Brenchley JM, Kilical Y, Gostick E, Sconocchia G, Hansmann K, Kurlander R, Douek DC, Barrett AJ. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy. 2007; 9(3):245-51. PMID: 17464756.
      Citations: 22     Fields:    Translation:HumansCells
    117. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, Rezvani K, Karimpour S, Childs R, Barrett AJ. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1261-9. PMID: 17162207.
      Citations: 15     Fields:    Translation:Humans
    118. Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1318-25. PMID: 17162214.
      Citations: 15     Fields:    Translation:HumansCells
    119. Li J, Melenhorst J, Hensel N, Rezvani K, Sconocchia G, Kilical Y, Hou J, Curfman B, Major E, Barrett AJ. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J Gen Virol. 2006 Oct; 87(Pt 10):2951-2960. PMID: 16963754.
      Citations: 20     Fields:    Translation:HumansCells
    120. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006 Aug 15; 108(4):1291-7. PMID: 16627754.
      Citations: 111     Fields:    Translation:HumansCellsCTClinical Trials
    121. Barrett J, Rezvani K. Neutrophil granule proteins as targets of leukemia-specific immune responses. Curr Opin Hematol. 2006 Jan; 13(1):15-20. PMID: 16319682.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    122. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, Li J, Mielke S, Douek DC, Barrett AJ. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8799-807. PMID: 16361568.
      Citations: 49     Fields:    Translation:HumansCells
    123. Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL, Rahemtulla A, Samson D, Apperley JF. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol. 2005 Nov; 75(5):376-83. PMID: 16191086.
      Citations: 16     Fields:    Translation:HumansCells
    124. Savani BN, Srinivasan R, Espinoza-Delgado I, Dorrance C, Takahashi Y, Igarashi T, Rezvani K, Lundqvist A, Barrett AJ, Childs RW. Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncol. 2005 Oct; 6(10):809-12. PMID: 16198987.
      Citations: 4     Fields:    Translation:HumansCells
    125. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, Leitman S, Read EJ, Childs R, Barrett AJ. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2006 Feb 15; 107(4):1688-95. PMID: 16131570.
      Citations: 40     Fields:    Translation:HumansCells
    126. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, Barrett AJ. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood. 2005 Nov 15; 106(10):3666-72. PMID: 16046526.
      Citations: 24     Fields:    Translation:HumansCells
    127. Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, Rezvani K, Price DA, Hensel NF, Douek DC, Barrett AJ. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res. 2005 Jun 15; 11(12):4495-503. PMID: 15958635.
      Citations: 13     Fields:    Translation:HumansCells
    128. Sconocchia G, Keyvanfar K, El Ouriaghli F, Grube M, Rezvani K, Fujiwara H, McCoy JP, Hensel N, Barrett AJ. Phenotype and function of a CD56+ peripheral blood monocyte. Leukemia. 2005 Jan; 19(1):69-76. PMID: 15526027.
      Citations: 17     Fields:    Translation:HumansCells
    129. Sconocchia G, Fujiwara H, Rezvani K, Keyvanfar K, El Ouriaghli F, Grube M, Melenhorst J, Hensel N, Barrett AJ. G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. J Leukoc Biol. 2004 Dec; 76(6):1214-9. PMID: 15345723.
      Citations: 6     Fields:    Translation:HumansCells
    130. Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Clin Cancer Res. 2004 Feb 01; 10(3):1047-56. PMID: 14871984.
      Citations: 7     Fields:    Translation:HumansCells
    131. Fujiwara H, El Ouriaghli F, Grube M, Price DA, Rezvani K, Gostick E, Sconocchia G, Melenhorst J, Hensel N, Douek DC, Barrett AJ. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood. 2004 Apr 15; 103(8):3076-83. PMID: 15070688.
      Citations: 13     Fields:    Translation:HumansCells
    132. El-Ouriaghli F, Sloand E, Mainwaring L, Fujiwara H, Keyvanfar K, Melenhorst JJ, Rezvani K, Sconocchia G, Solomon S, Hensel N, Barrett AJ. Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. Blood. 2003 Nov 15; 102(10):3786-92. PMID: 12893759.
      Citations: 5     Fields:    Translation:HumansCells
    133. Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, Gostick E, Yamada K, Melenhorst J, Childs R, Hensel N, Douek DC, Barrett AJ. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003 Oct 15; 102(8):2892-900. PMID: 12829610.
      Citations: 55     Fields:    Translation:HumansCells
    134. Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program. 2003; 350-71. PMID: 14633790.
      Citations: 12     Fields:    Translation:HumansCells
    135. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, Rezvani K, Craddock C, Rassam S, Prentice HG. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol. 2001 Dec; 115(3):622-9. PMID: 11736947.
      Citations: 12     Fields:    Translation:Humans
    136. Pocock CF, Lucas GF, Giles C, Vassiliou G, Cwynarski K, Rezvani K, Apperley JF, Goldman JM. Immune neutropenia associated with anti-human neutrophil antigen-2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony-stimulating factor. Br J Haematol. 2001 May; 113(2):483-5. PMID: 11380420.
      Citations: 3     Fields:    Translation:Humans
    137. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, Craddock C, Apperley JF, Cross NC, Goldman JM. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2001 Mar 15; 97(6):1560-5. PMID: 11238091.
      Citations: 22     Fields:    Translation:Humans
    138. Pocock C, Szydlo R, Davis J, de La Fuente J, Craddock C, Cwynarski K, Olavarria E, Rezvani K, Kanfer E, Apperley J, Goldman J. Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. Hematol J. 2001; 2(4):265-72. PMID: 11920259.
      Citations:    Fields:    Translation:HumansCells
    139. Rezvani K, Flanagan AM, Sarma U, Constantinovici N, Bain BJ. Investigation of ethnic neutropenia by assessment of bone marrow colony-forming cells. Acta Haematol. 2001; 105(1):32-7. PMID: 11340251.
      Citations: 8     Fields:    Translation:HumansCells
    140. Phillips D, Rezvani K, Bain BJ. Exercise induced mobilisation of the marginated granulocyte pool in the investigation of ethnic neutropenia. J Clin Pathol. 2000 Jun; 53(6):481-3. PMID: 10911809.
      Citations: 11     Fields:    Translation:HumansCells
    141. Rezvani K, Bain BJ, Coulter CA. Loss of singing ability caused by vincristine. Clin Lab Haematol. 1998 Feb; 20(1):47-8. PMID: 9681210.
      Citations: 2     Fields:    Translation:Humans
    142. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 122:3316-3326.
    143. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 102:110-117.
    144. Epigenetic landscape of the TERT promoter. British Journal of Haematology.
    145. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma. Blood. 96.
    146. Membranous nephropathy in autologous hematopoietic stem cell transplant. CKJ: Clinical Kidney Journal. 8:440-444.
    147. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy.
    148. The application of natural killer cell immunotherapy for the treatment of cancer. Frontiers in Immunology. 6.
    149. Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research. 22:2359-2367.
    150. UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells. Blood. 127:2575-2586.
    151. CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines. Journal of Translational Medicine. 3.
    152. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. American Journal of Transplantation.
    153. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 128:297-312.
    154. Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Molecular Diagnostics. 18:638-642.
    155. STAT3. Blood. 123:1-2.
    156. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence. 1-16.
    157. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 100:1361-1370.
    158. Phase i trials using sleeping beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation. 126:3363-3376.
    159. Comparison of two methodologies for the enrichment of mononuclear cells from thawed cord blood products. Cytotherapy. 19:433-439.
    160. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation.
    161. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation. 21:1284-1290.
    162. Peptide Vaccines for Myeloid Leukemias. 596-602.
    163. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Frontiers in Immunology. 6.
    164. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transplant Infectious Disease.
    165. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy. 18:995-1001.
    166. Implementation of a pan-genomic approach to investigate holobiont-infecting microbe interaction. PLoS One. 10.
    167. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leukemia and Lymphoma. 1-9.
    168. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation.
    169. The role of regulatory T cells in GVL and GVHD. 117-135.
    170. The importance of patient selection in nonmyeloablative stem cell transplant (NMSCT) for acute and chronic leukaemia, myelodysplastic syndrome, and myeloma. Blood. 96.
    171. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 99:836-847.
    172. Epstein-Barr virus and B cells in the pathogenesis of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation. Journal of Clinical Oncology. 34:2201-2202.
    173. Utility of the enzyme-linked immunospot interferon-γ- release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. Journal of Infectious Diseases. 213:1701-1707.
    174. Donor lymphocyte infusions (dli) for cml. Blood. 96.
    175. The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia.
    176. Cytotherapy. 18:1312-1324.
    177. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 23:285-292.
    178. Umbilical cord blood graft engineering. Bone Marrow Transplantation. 50:S55-S62.
    REZVANI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (567)
    Explore
    _
    Co-Authors (94)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _